Skip to content
Parker Institute for Cancer Immunotherapy
Search Close


A Study of Novel Immunotherapy Combinations for Metastatic Pancreatic Cancer

Why This Trial

Pancreatic cancer is not only one of the deadliest tumor types, and it’s becoming more common. It is also complex, with a variety of cell types, pathways and processes which make it resistant to most single therapies. This means defeating it will require the right combination of treatments.

About the Study

REVOLUTION uses what’s called a platform trial design, which allows our researchers to be flexible in ways that streamline the complicated process of setting up a clinical trial. It allows researchers to test different therapies and approaches at the same time, and it gives them the option to expand the size of each arm if the evidence suggests they should.

REVOLUTION currently consists of two arms.

Cohort A will test a combination of standard-of-care chemotherapy, the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab. In addition to providing valuable information on the efficacy of the combination itself, this cohort builds on the findings from PRINCE that suggested chemotherapy and PD-1 treatment combined may improve survival.

Cohort B will investigate chemotherapy, ipilimumab and hydroxychloroquine (HCQ). HCQ is a drug designed to stop a process called autophagy, when cancer cells recycle their own materials to survive – a potentially key process in pancreatic cancer.

Where We’re At Now

The trial initially opened for enrollment in May 2021. Both Cohort A and Cohort B are currently enrolling patients.



Site Investigators

  • George Fisher, MD, PhD | Stanford Medicine
  • Andrew Ko, MD | University of California, San Francisco
  • Mark O’Hara, MD | University of Pennsylvania
  • Eileen O’Reilly, MD | Memorial Sloan Kettering Cancer Center
  • Osama Rama, MD | Dana Farber Cancer Institute
  • Zev Wainberg, MD | University of California, Los Angeles
  • Robert Wolff, MD | The University of Texas MD Anderson Cancer Center


For more information on this trial (NCT04787991), visit

Support Our Work

To join PICI to support life-saving work like this, donate now or contact